Drugmaker Gilead Sciences again reported record growth as sales of its hepatitis C blockbuster Sovaldi topped $2.8 billion in the third quarter of the year.
Stephen Ubl, president and CEO of the Advanced Medical Technology Association, discusses the potential impact of new payment models, as well as regulatory and tax issues, on the $110 billion device industry. He spoke with Modern Healthcare reporter Sabriya Rice.
Johnson & Johnson reported higher-than-expected third-quarter earnings, fueled in the U.S. market by a 33% increase in drug sales and a modest uptick in hospital utilization rates.
Despite its numerous advantages, minimally invasive surgery (MIS) is widely under-utilized in the United States, as we shared in a recent post. “MIS is increasingly recognized as a better option for patients due to the lower cost, quicker recovery and fewer risks for complications compared...
Kimberly-Clark Corp. has set Oct. 31 as the spinoff date for its healthcare business. The divestiture will create a new publicly traded company, Halyard Health, according to a recent Kimberly-Clark Securities and Exchange Commission filing.
As West Africa's Ebola outbreak continues to rage, some experts are coming to the conclusion that it may take large amounts of vaccines and maybe even drugs to bring the outbreak under control.
Pharmaceutical giant Genentech has come under a maelstrom of criticism from hospitals for its decision to change its distribution methods for three widely used cancer drugs, and now the nation's largest not-for-profit health system is responding with a bold message.
Federal officials are planning to sharply increase production of ZMapp, which is viewed by many experts as the most promising experimental drug for treating people infected with Ebola in West Africa.
The CMS' publication Tuesday of industry payments to healthcare providers included financial support for clinical research at teaching hospitals.
As more healthcare organizations move toward a value-based care reimbursement model, it may seem that nothing short of complete system overhaul will allow organizations to meet every one of the patient-centered goals laid out by the Affordable Care Act.
Drugmaker Hospira said Wednesday that it received a warning letter from the Food and Drug Administration regarding poor manufacturing quality at one of its facilities in Australia.
Drugmaker Genentech is changing the way it ships three high-profile cancer drugs to hospitals, which are concerned that the new process will grossly inflate their already high costs and potentially affect patient care. Genentech contends the change is designed to ensure patient safety and access to...